Search alternatives:
marked decrease » marked increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
marked decrease » marked increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1
Development of Selective and Soluble Mitochondrial Complex 1 Inhibitors Derived from Papaverine for Radiosensitization of Cancer
Published 2025“…Papaverine is typically used as a vasorelaxant due to its ability to inhibit phosphodiesterase 10A (PDE10A), which can lead to unwanted side effects when used clinically as a radiosensitizer. …”
-
2
Development of Selective and Soluble Mitochondrial Complex 1 Inhibitors Derived from Papaverine for Radiosensitization of Cancer
Published 2025“…Papaverine is typically used as a vasorelaxant due to its ability to inhibit phosphodiesterase 10A (PDE10A), which can lead to unwanted side effects when used clinically as a radiosensitizer. …”
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
Group-level narrow- and broad-band spectral changes after hemispherotomy reveal a marked EEG slowing of the isolated cortex, robust across patients.
Published 2025“…This decrease was larger in the disconnected than in the contralateral cortex. …”
-
11
Image 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.pdf
Published 2025“…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”
-
12
Table 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx
Published 2025“…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”
-
13
Table 2_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx
Published 2025“…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”
-
14
Image 2_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.pdf
Published 2025“…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”
-
15
Variables of trees located at coordinates .
Published 2025“…Furthermore, uncertainty analysis showed that the mean MSI of the population decreased over a 100-year period without weevil predation, and this trend was exacerbated by the presence of weevil predation.…”
-
16
Global parameters and variables for the model.
Published 2025“…Furthermore, uncertainty analysis showed that the mean MSI of the population decreased over a 100-year period without weevil predation, and this trend was exacerbated by the presence of weevil predation.…”
-
17
Variables of patch located at coordinates .
Published 2025“…Furthermore, uncertainty analysis showed that the mean MSI of the population decreased over a 100-year period without weevil predation, and this trend was exacerbated by the presence of weevil predation.…”
-
18
MRSP Data collected in March 2018.
Published 2025“…Furthermore, uncertainty analysis showed that the mean MSI of the population decreased over a 100-year period without weevil predation, and this trend was exacerbated by the presence of weevil predation.…”
-
19
Data Sheet 1_CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint.docx
Published 2025“…Notably, the silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.…”
-
20
Data Sheet 1_Persistent lymphopenia after kidney transplantation: increased mortality and decreased homeostatic mechanisms.docx
Published 2025“…The major risk factors for lymphopenia at 3 years were: receiving alemtuzumab or rATG for induction or the treatment of rejection, increasing recipient age, pretransplant dialysis, a low lymphocyte count pretransplant, and having a prior kidney transplant. …”